ASA404 enters second Ph III NSCLC study

19 January 2009

UK cancer drug developer Antisoma says that ATTRACT-2, a Phase III trial testing ASA404 as a second-line treatment for non-small cell lung  cancer, is now underway.

This is a single pivotal study designed to support applications to  market ASA404 for lung cancer patients who have received one previous  round of treatment.

A separate, ongoing pivotal trial, ATTRACT-1, is evaluating the  tumor-vascular disrupting agent in patients receiving their first  treatment for NSCLC.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight